Trial Profile
An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Retigabine (Primary) ; Antiepileptic drugs
- Indications Partial epilepsies
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 28 Aug 2017 Status changed from recruiting to discontinued.
- 28 Sep 2016 Planned End Date changed from 1 Feb 2019 to 1 Nov 2025.
- 28 Sep 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Nov 2025.